The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

Roman Hajek; David Siegel; Robert Z. Orlowski; Heinz Ludwig; Antonio Palumbo; Meletios Dimopoulos

doi:10.3109/10428194.2013.797084

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

Roman Hajek, David Siegel, Robert Z. Orlowski, Heinz Ludwig, Antonio Palumbo, Meletios Dimopoulos

Lymphoma-Myeloma

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Clinical outcomes for patients with multiple myeloma (MM) have improved substantially since the introduction of novel agents including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide. However, most patients with MM eventually relapse, and prognosis remains poor among patients with relapsed and/or refractory disease. Combination therapy using agents with different mechanisms of action is emerging as an attractive treatment approach in oncology to increase efficacy and/or overcome resistance to standard treatment regimens. This review discusses unmet needs in the treatment of MM and the development of histone deacetylase inhibitors as a treatment modality for MM.

Original language	English (US)
Pages (from-to)	11-18
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	55
Issue number	1
DOIs	https://doi.org/10.3109/10428194.2013.797084
State	Published - Jan 2014

Keywords

Bortezomib
Histone deacetylase inhibitor
Immunomodulatory drug
Multiple myeloma
Proteasome inhibitor

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.3109/10428194.2013.797084

Cite this

@article{c6ed06a3bc1a4c87a0482649d8718ba1,

title = "The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma",

abstract = "Clinical outcomes for patients with multiple myeloma (MM) have improved substantially since the introduction of novel agents including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide. However, most patients with MM eventually relapse, and prognosis remains poor among patients with relapsed and/or refractory disease. Combination therapy using agents with different mechanisms of action is emerging as an attractive treatment approach in oncology to increase efficacy and/or overcome resistance to standard treatment regimens. This review discusses unmet needs in the treatment of MM and the development of histone deacetylase inhibitors as a treatment modality for MM.",

keywords = "Bortezomib, Histone deacetylase inhibitor, Immunomodulatory drug, Multiple myeloma, Proteasome inhibitor",

author = "Roman Hajek and David Siegel and Orlowski, {Robert Z.} and Heinz Ludwig and Antonio Palumbo and Meletios Dimopoulos",

note = "Funding Information: Medical writing and editorial assistance was provided by Joseph J. Abrajano, PhD, and Kakuri M. Omari, PhD, of Inte-grus Scientific, a division of Medicus International New York (New York, NY). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (White-house Station, NJ). The authors were fully responsible for all content and editorial decisions and received no financial support or other compensation related to the development of the manuscript. All individuals mentioned in this section have provided written permission.",

year = "2014",

month = jan,

doi = "10.3109/10428194.2013.797084",

language = "English (US)",

volume = "55",

pages = "11--18",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

AU - Hajek, Roman

AU - Siegel, David

AU - Orlowski, Robert Z.

AU - Ludwig, Heinz

AU - Palumbo, Antonio

AU - Dimopoulos, Meletios

N1 - Funding Information: Medical writing and editorial assistance was provided by Joseph J. Abrajano, PhD, and Kakuri M. Omari, PhD, of Inte-grus Scientific, a division of Medicus International New York (New York, NY). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (White-house Station, NJ). The authors were fully responsible for all content and editorial decisions and received no financial support or other compensation related to the development of the manuscript. All individuals mentioned in this section have provided written permission.

PY - 2014/1

Y1 - 2014/1

N2 - Clinical outcomes for patients with multiple myeloma (MM) have improved substantially since the introduction of novel agents including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide. However, most patients with MM eventually relapse, and prognosis remains poor among patients with relapsed and/or refractory disease. Combination therapy using agents with different mechanisms of action is emerging as an attractive treatment approach in oncology to increase efficacy and/or overcome resistance to standard treatment regimens. This review discusses unmet needs in the treatment of MM and the development of histone deacetylase inhibitors as a treatment modality for MM.

AB - Clinical outcomes for patients with multiple myeloma (MM) have improved substantially since the introduction of novel agents including the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide. However, most patients with MM eventually relapse, and prognosis remains poor among patients with relapsed and/or refractory disease. Combination therapy using agents with different mechanisms of action is emerging as an attractive treatment approach in oncology to increase efficacy and/or overcome resistance to standard treatment regimens. This review discusses unmet needs in the treatment of MM and the development of histone deacetylase inhibitors as a treatment modality for MM.

KW - Bortezomib

KW - Histone deacetylase inhibitor

KW - Immunomodulatory drug

KW - Multiple myeloma

KW - Proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84891365148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891365148&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.797084

DO - 10.3109/10428194.2013.797084

M3 - Review article

C2 - 23614765

AN - SCOPUS:84891365148

SN - 1042-8194

VL - 55

SP - 11

EP - 18

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this